BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 11196150)

  • 1. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
    End DW; Smets G; Todd AV; Applegate TL; Fuery CJ; Angibaud P; Venet M; Sanz G; Poignet H; Skrzat S; Devine A; Wouters W; Bowden C
    Cancer Res; 2001 Jan; 61(1):131-7. PubMed ID: 11196150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.
    Kelland LR; Smith V; Valenti M; Patterson L; Clarke PA; Detre S; End D; Howes AJ; Dowsett M; Workman P; Johnston SR
    Clin Cancer Res; 2001 Nov; 7(11):3544-50. PubMed ID: 11705875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery.
    Venet M; End D; Angibaud P
    Curr Top Med Chem; 2003; 3(10):1095-102. PubMed ID: 12769710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.
    Le Gouill S; Pellat-Deceunynck C; Harousseau JL; Rapp MJ; Robillard N; Bataille R; Amiot M
    Leukemia; 2002 Sep; 16(9):1664-7. PubMed ID: 12200678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
    Buzzeo R; Enkemann S; Nimmanapalli R; Alsina M; Lichtenheld MG; Dalton WS; Beaupre DM
    Clin Cancer Res; 2005 Aug; 11(16):6057-64. PubMed ID: 16115951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor.
    O'Meara SJ; Kinsella BT
    Br J Pharmacol; 2004 Sep; 143(2):318-30. PubMed ID: 15339863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro.
    Ochiai N; Uchida R; Fuchida S; Okano A; Okamoto M; Ashihara E; Inaba T; Fujita N; Matsubara H; Shimazaki C
    Blood; 2003 Nov; 102(9):3349-53. PubMed ID: 12842991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma.
    Rolland D; Camara-Clayette V; Barbarat A; Salles G; Coiffier B; Ribrag V; Thieblemont C
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):855-63. PubMed ID: 17639395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.
    Delmas C; End D; Rochaix P; Favre G; Toulas C; Cohen-Jonathan E
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6062-8. PubMed ID: 14676133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Lipari P; Malkowski M; Ferrari E; Nielsen L; Prioli N; Dell J; Sinha D; Syed J; Korfmacher WA; Nomeir AA; Lin CC; Wang L; Taveras AG; Doll RJ; Njoroge FG; Mallams AK; Remiszewski S; Catino JJ; Girijavallabhan VM; Bishop WR
    Cancer Res; 1998 Nov; 58(21):4947-56. PubMed ID: 9810004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.
    Caraglia M; D'Alessandro AM; Marra M; Giuberti G; Vitale G; Viscomi C; Colao A; Prete SD; Tagliaferri P; Tassone P; Budillon A; Venuta S; Abbruzzese A
    Oncogene; 2004 Sep; 23(41):6900-13. PubMed ID: 15286715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line.
    Smith V; Rowlands MG; Barrie E; Workman P; Kelland LR
    Clin Cancer Res; 2002 Jun; 8(6):2002-9. PubMed ID: 12060646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel.
    Nakamura K; Yamaguchi A; Namiki M; Ishihara H; Nagasu T; Kowalczyk JJ; Garcia AM; Lewis MD; Yoshimatsu K
    Oncol Res; 2001; 12(11-12):477-84. PubMed ID: 11939411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells.
    Nagase T; Kawata S; Tamura S; Matsuda Y; Inui Y; Yamasaki E; Ishiguro H; Ito T; Miyagawa J; Mitsui H; Yamamoto K; Kinoshita M; Matsuzawa Y
    Br J Cancer; 1997; 76(8):1001-10. PubMed ID: 9376258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways.
    Caraglia M; Marra M; Viscomi C; D'Alessandro AM; Budillon A; Meo G; Arra C; Barbieri A; Rapp UR; Baldi A; Tassone P; Venuta S; Abbruzzese A; Tagliaferri P
    Int J Cancer; 2007 Nov; 121(10):2317-30. PubMed ID: 17657738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.
    Nagasu T; Yoshimatsu K; Rowell C; Lewis MD; Garcia AM
    Cancer Res; 1995 Nov; 55(22):5310-4. PubMed ID: 7585593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.